


Atty. Dkt. No. 072827-2002

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Presently amended) A compound having the chemical formula:



wherein R₁ is selected from the group consisting of: heteroaryl and heterocycloalk;

R₂ is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =O, C(O)OH, C(O)O-lower alk, C(O)NH-lower alk, C(O)N(lower alk)₂, SH, S-lower alk, NH₂, NH-lower alk, and N(lower alk)₂,

R₃ and R₄ is each independently lower alk or together cyclopropyl;

R₅ is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, or a substituted phenyl having one to four substituents with at least one substituent in a *meta* or *para* position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy,

provided that said substituted phenyl may also have 2 to 3 additional substituents;

R₆ if present is either hydrogen, lower alkyl or lower alkenyl, wherein R₆ is not present if R₂ is =O;

Y₁ is either covalent bond, alkylene, or alkenylene;

Atty. Dkt. No. 072827-2002

Y_2 is alkylene;

Y_3 is alkylene;

Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene,

provided that R_1 is not pyridyl, benzydioxy, or thiophene;

provided that if Z is either O, S, NH, or N-lower alk, then Y_1 is not a covalent bond; further provided that Y_1 and Z may together be a covalent bond;

further provided that if R_5 is 3, 4 dimethoxy-phenyl, then R_1 is not ~~$CH_3(CH_2)_5O$ -phenyl; 2-cyclopentyl-phenyl; 2-Cl-phenyl; 2-CN-phenyl; 2-(3-furanyl)-phenyl; or 4-benzo(d)isothiazole;~~

further provided that if R_5 is 4-methoxy-phenyl, then R_1 is not ~~2-cyclopentyl-phenyl; 2- CH_3 -phenyl; 2-benzyl-phenyl; 3- CH_3 -phenyl; 4- CH_3SO_2 -phenyl; 4-benzo(d)isothiazole;~~

further provided that if R_5 is 4-Cl-phenyl, then R_1 is not ~~2- CH_3 -phenyl; 5-iso-propyl-phenyl; 4- CH_3 -phenyl; phenyl; 2-Cl-phenyl; 4-Cl-phenyl; 2-methoxy; 4- CH_3CHCH -phenyl; 3,4- CH_3 -phenyl; 2,4- CH_3 -phenyl; 2,3- CH_3 -phenyl; 2-iso-propyl; 5- CH_3 -phenyl; pyridyl; 1-imidazole; or 4-benzo(d)isothiazole; and~~

~~further provided that if R_5 is 3,5 dimethyl, 4-methoxy-phenyl, then R_1 is not 4- CH_3 , 6-CN-2-pyridyl, 3-CN-pyridyl; and~~

pharmaceutically acceptable salts and complexes thereof;

wherein said compound has an $IC_{50} \leq 10 \mu M$ using the Calcium Receptor Inhibitor Assay.

2. (Original) The compound of claim 1, wherein:

Y_1 is methylene;

Atty. Dkt. No. 072827-2002

Y_2 is methylene; and

Y_3 is methylene.

3. (Original) The compound of any of claims 1-2, wherein

R_2 is OH or methoxy,

R_6 is hydrogen,

R_3 or R_4 is independently methyl or ethyl; and

Z is O, S, or unsubstituted alkylene.

4. (Original) The compound of claim 3, wherein R_2 is OH, and Z is O.

5. (Original) The compound of claims 1-2, wherein

R_2 is hydrogen,

R_6 is hydrogen,

R_3 and R_4 is independently methyl or ethyl; and

Z is O or methylene.

6. (Presently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claims ~~1-3~~ 1-2.

7-31 (Withdrawn - list)

32. (New) The compound of claim 1 wherein R_1 is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinolinyl, isoquinolinyl, and heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower

Atty. Dkt. No. 072827-2002


haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, NO₂, NH₂, and OH.

33. (New) The compound of claim 3 wherein R₁ is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinoliny, isoquinoliny, and heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, NO₂, NH₂, and OH.

34. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 3.

Atty. Dkt. No. 072827-2002

35. (New) A compound having the chemical formula:



wherein R₁ is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinoliny, isoquinoliny, and heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, NO₂, NH₂, and OH;

R₂ is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =O, C(O)OH, C(O)O-lower alk, C(O)NH-lower alk, C(O)N(lower alk)₂, SH, S-lower alk, NH₂, NH-lower alk, and N(lower alk)₂,

R₃ and R₄ is each independently lower alk or together cyclopropyl;

R₅ is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, or a substituted phenyl having one to four substituents with at least one substituent in a *meta* or *para* position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy, provided that said substituted phenyl may also have 2 to 3 additional substituents;

R₆ if present is either hydrogen, lower alkyl or lower alkenyl, wherein R₆ is not present if R₂ is =O;

Y₁ is either covalent bond, alkylene, or alkenylene;

Atty. Dkt. No. 072827-2002

Y_2 is alkylene;

Y_3 is alkylene;

Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either O, S, NH, or N-lower alk, then Y_1 is not a covalent bond; further provided that Y_1 and Z may together be a covalent bond; and

pharmaceutically acceptable salts and complexes thereof;

wherein said compound has an $IC_{50} \leq 10 \mu M$ using the Calcium Receptor Inhibitor Assay.

36. (New) The compound of claim 35, wherein:

Y_1 is methylene;

Y_2 is methylene; and

Y_3 is methylene.

37. (New) The compound of any of claims 34-35, wherein

R_2 is OH or methoxy,

R_6 is hydrogen,

R_3 or R_4 is independently methyl or ethyl; and

Z is O, S, or unsubstituted alkylene.

38. (New) The compound of claim 36, wherein R_2 is OH, and Z is O.

39. (New) The compound of claims 34-35, wherein

R_2 is hydrogen,

Atty. Dkt. No. 072827-2002

R_6 is hydrogen,

R_3 and R_4 is independently methyl or ethyl; and

Z is O or methylene.

40. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claims 34-35.